Not Signed In - Teva Announces Tentative Approval For Generic Risperdal® Oral Solution
Sun, 15 Oct 2006 07:00 AM EST
... Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Janssen's Risperdal® (Risperidone) Oral Solution, 1 mg/mL. Final approval is expected upon expiry of patent protection for the brand product on December 29, 2007. [click link for full article] ...
Related Topics
- Ergocalciferol, Vitamin D2 Oral Solution
- Stavudine Oral Solution
- Cyclosporine Oral Solution
- Alendronate Oral Solution
- Escitalopram Oral Solution
- Gabapentin Oral Solution
- Acetaminophen and Oxycodone Oral Solution
- Lopinavir and Ritonavir Oral Solution
- Sirolimus Oral Solution
- Rivastigmine Oral Solution
- Galantamine Oral Solution
- Furosemide Oral Solution
- Neomycin Oral Solution
- Fluoxetine Oral Solution
- Amprenavir Oral Solution
- Ribavirin Oral Solution
- Sertraline Oral Solution
- Trimethoprim Oral Solution
- Methadone Oral Solution
- Ethosuximide Oral Solution
email this page
print this page
bookmark this page
feedback on this page
